Drill Craig A Lowers stake in BioTelemetry (BEAT)

BioTelemetry (BEAT) : Drill Craig A reduced its stake in BioTelemetry by 25.91% during the most recent quarter end. The investment management company now holds a total of 678,773 shares of BioTelemetry which is valued at $10.2 Million after selling 237,400 shares in BioTelemetry , the firm said in a disclosure report filed with the SEC on May 11, 2016.BioTelemetry makes up approximately 25.37% of Drill Craig A’s portfolio.

Other Hedge Funds, Including , Trexquant Investment Lp reduced its stake in BEAT by selling 9,968 shares or 21.73% in the most recent quarter. The Hedge Fund company now holds 35,895 shares of BEAT which is valued at $538,066. BioTelemetry makes up approx 0.06% of Trexquant Investment Lp’s portfolio. Airain Ltd sold out all of its stake in BEAT during the most recent quarter. The investment firm sold 20,217 shares of BEAT which is valued $303,053.Nine Chapters Capital Management reduced its stake in BEAT by selling 27,200 shares or 51.71% in the most recent quarter. The Hedge Fund company now holds 25,400 shares of BEAT which is valued at $380,746. BioTelemetry makes up approx 0.03% of Nine Chapters Capital Management’s portfolio. Alambic Investment Management added BEAT to its portfolio by purchasing 28,300 company shares during the most recent quarter which is valued at $427,613. BioTelemetry makes up approx 0.14% of Alambic Investment Management’s portfolio.Nationwide Fund Advisors reduced its stake in BEAT by selling 1,170 shares or 6.4% in the most recent quarter. The Hedge Fund company now holds 17,118 shares of BEAT which is valued at $258,653.

BioTelemetry opened for trading at $14.96 and hit $15.32 on the upside on Monday, eventually ending the session at $15.31, with a gain of 2.13% or 0.32 points. The heightened volatility saw the trading volume jump to 4,89,017 shares. Company has a market cap of $427 M.

On the company’s financial health, BioTelemetry reported $0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.10. The company had revenue of $48.60 million for the quarter, compared to analysts expectations of $46.54 million. The company’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 EPS.

Leave a Reply

BioTelemetry - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioTelemetry. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.